You don't have javascript enabled. Good luck with that.
Skip to content

FOR US HEALTHCARE PROFESSIONALS

Adbry is strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2

Adbry Pediatric Efficacy (Ages 12-17)

Putting in the work For clearer skin and itch relief3,4

AS LITTLE AS $0

For eligible patientsa

With Copay
Savings

EASI-75

Pediatric patients achieving
EASI-75 at Week 164*†

Pediatric patients achieving EASI-75 at Week 164*†

Pediatric patients achieving EASI-75 at week 16. Patients achieving EASI-75, Adbry® (tralokinumab-idrm) 150 mg was 29% and placebo was 6%. Greater than four times as many patients for Adbry® (tralokinumab-idrm).

EASI-75=improvement of at least 75% in Eczema Area and Severity Index; EASI-90=improvement of at least 90% in EASI; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed. †Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

At Week 16, more than 4x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of EASI-75 compared with placebo3

In ECZTRA 6, a higher proportion of subjects in the Adbry 150 mg every-other-week group achieved EASI-90 compared with placebo3

IGA 0/1

Pediatric patients achieving IGA 0/1 at Week 164*†

Pediatric patients achieving EASI-75 at week 16. Patients achieving IGA 0/1, Adbry® (tralokinumab-idrm) 150 mg was 21% and placebo was 4%. Greater than fives times as many patients for Adbry® (tralokinumab-idrm).

IGA 0/1=Score of 0/1 using the Investigator’s Global Assessment scale; q2w=every 2 weeks.

* Full Analysis Set (FAS) includes all subjects randomized and dosed. †Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders.

At Week 16, more than 5x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of IGA 0/1 compared with placebo3

At Week 16, more than 5x as many patients treated with Adbry 150 mg q2w monotherapy achieved the primary endpoint of IGA 0/1 compared with placebo3

Itch NRS

Patients experienced significant
itch relief at Week 163,4

Percentage of patients achieving a ≥4-point improvement in
Adolescent Worst Pruritus NRS at Week 164*†‡

Percentage of patients achieving a > 4-point improvement in adolescent worst pruritus NRS at week 16. Of the patients, 23% of Adbry® (tralokinumab-idrm) 150 mg patients achieved while 3% of placebo achieved. Greater than seven times as many patients for Adbry® (tralokinumab-idrm).

NRS=Numeric Rating Scale; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed. †Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders. ‡Subjects with baseline Adolescent Worst Pruritus NRS (weekly average) ≥4.

At Week 16, more than 7x as many patients treated with Adbry 150 mg q2w monotherapy experienced reduction of ≥4 points in Adolescent Worst Pruritus NRS compared with placebo3

NRS=Numeric Rating Scale; q2w=every 2 weeks.

*Full Analysis Set (FAS) includes all subjects randomized and dosed. †Subjects who received rescue treatment from Week 2 to Week 16 or had missing data were considered nonresponders. ‡Subjects with baseline Adolescent Worst Pruritus NRS (weekly average) ≥4.

Explore
Dosing

Explore Dosing

View
Coverage

View Coverage